Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Operating Margin (2020 - 2025)

Cytek Biosciences' Operating Margin history spans 6 years, with the latest figure at 9.0% for Q4 2025.

  • For Q4 2025, Operating Margin fell 1420.0% year-over-year to 9.0%; the TTM value through Dec 2025 reached 20.04%, down 980.0%, while the annual FY2025 figure was 20.04%, 980.0% down from the prior year.
  • Operating Margin reached 9.0% in Q4 2025 per CTKB's latest filing, up from 17.58% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 12.53% in Q2 2021 to a low of 36.12% in Q1 2025.
  • Average Operating Margin over 5 years is 8.87%, with a median of 7.49% recorded in 2022.
  • Peak YoY movement for Operating Margin: surged 1367bps in 2021, then plummeted -2607bps in 2023.
  • A 5-year view of Operating Margin shows it stood at 1.52% in 2021, then soared by 111bps to 0.17% in 2022, then tumbled by -235bps to 0.24% in 2023, then skyrocketed by 2308bps to 5.2% in 2024, then tumbled by -273bps to 9.0% in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Operating Margin are 9.0% (Q4 2025), 17.58% (Q3 2025), and 23.3% (Q2 2025).